Loading…
HUTCHMED (China) Limited is projected to rise to $11.84 by 2027, a +7% move from its current price of $11.07. HCM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.84 | $11.07 | $11.30 | -0.02% |
| Jul 14 | $10.74 | $11.06 | $11.40 | -0.05% |
| Jul 15 | $10.67 | $11.06 | $11.47 | -0.07% |
| Jul 16 | $10.60 | $11.06 | $11.53 | -0.10% |
| Jul 17 | $10.55 | $11.06 | $11.59 | -0.12% |
| Jul 18 | $10.50 | $11.05 | $11.64 | -0.15% |
| Jul 19 | $10.45 | $11.05 | $11.68 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.45 | $11.05 | $11.68 | -0.17% |
| Week 2 | $10.20 | $11.03 | $11.93 | -0.34% |
| Week 3 | $10.00 | $11.01 | $12.13 | -0.51% |
| Week 4 | $9.84 | $10.99 | $12.29 | -0.68% |
| Week 5 | $9.69 | $10.98 | $12.43 | -0.85% |
| Week 6 | $9.56 | $10.96 | $12.55 | -1.02% |
| Week 7 | $9.44 | $10.94 | $12.67 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutant AML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc.
The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited trades under the symbol HCM and is currently priced at $11.65. Its market capitalization is $2B and it is ranked 2022. The long-run forecast shows notable upside, with 2030 avg $16.67 and max $23.13 (ROI 43.1), 2040 avg $28.40 and max $44.56 (ROI 143.8), and 2050 avg $59.27 and max $100.27 (ROI 408.7).
Near-term projections also outline a gradual rise from 2026–2029, with 2026 min $9.99, avg $11.65, max $14.64 (ROI 0), 2027 min $10.10, avg $12.43, max $16.05 (ROI 6.7), 2028 min $10.36, avg $13.02, max $17.31 (ROI 11.8), and 2029 min $10.53, avg $13.46, max $18.31 (ROI 15.5).
A major floor 16.5% below — a decisive break under it would weaken the trend.
The nearest floor, 9.8% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 42.2% above — clearing it would confirm fresh momentum.
Key HCM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HCM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.18 | Sell | $11.07 | Sell |
| MA 10 | $10.98 | Buy | $10.98 | Buy |
| MA 20 | $10.69 | Buy | $10.95 | Buy |
| MA 50 | $11.57 | Sell | $11.62 | Sell |
| MA 100 | $13.06 | Sell | $12.57 | Sell |
| MA 200 | $13.92 | Sell | $13.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.05 | Neutral |
| Stoch RSI (14) | 70.61 | Neutral |
| CCI (20) | 66.87 | Neutral |
| Williams %R (14) | -34.94 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 8.96 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 65.06 | Neutral |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 58.38 | Neutral |
| Momentum (10) | 0.78 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 11.10 | Sell |
| ADX (14) | 25.29 | Buy |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is NEUTRAL. RSI 14 sits at 60. Price is trading near the SMA50 of $11.78 and below the SMA200 of $14.04. Near-term support is at $9.99 and resistance at $12.04. The 30-day price range spans from $10.14 to $13.39, highlighting a contained trading corridor. Annualized volatility is 40.0, reflecting notable near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $11.07 | $13.87 | 0% | Neutral | |
| $9.63 | $11.84 | $15.27 | +7% | Neutral | |
| $9.97 | $12.53 | $16.64 | +13% | Neutral | |
| $10.09 | $12.89 | $17.52 | +16% | Neutral | |
| $12.33 | $15.99 | $22.17 | +44% | Bullish | |
| $13.59 | $17.88 | $25.21 | +61% | Bullish | |
| $13.06 | $17.39 | $24.91 | +57% | Bullish | |
| $13.93 | $18.78 | $27.28 | +70% | Bullish | |
| $14.18 | $19.32 | $28.44 | +75% | Bullish | |
| $14.57 | $20.06 | $29.88 | +81% | Bullish | |
| $19.26 | $27.83 | $43.62 | +151% | Bullish | |
| $36.92 | $57.83 | $97.69 | +422% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.99 | $11.07 | $13.05 | +0.00% |
| August 2026 | $9.17 | $10.75 | $12.90 | -2.87% |
| September 2026 | $9.18 | $10.83 | $13.10 | +0.69% |
| October 2026 | $9.43 | $11.17 | $13.62 | +3.21% |
| November 2026 | $9.45 | $11.23 | $13.78 | +0.54% |
| December 2026 | $9.42 | $11.24 | $13.87 | +0.10% |
Click any year to see its month-by-month HCM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HCM price prediction for 2026 points to an average of $11.07 (low $9.99, high $13.87) — a potential gain of 0% on today's $11.07. A consolidation phase looks the most probable path here.
In 2027, HCM is projected to trade between $9.63 and $15.27, averaging $11.84 — a potential gain of +7% from today's $11.07. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
HUTCHMED (China) Limited's 2028 outlook centres on $12.53, within a $9.97 to $16.64 range. That is up +6% on the projected 2027 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, HCM could reach as high as $17.52, with a base case around $12.89 and support toward $10.09 — roughly +16% from $11.07. Price action looks broadly range-bound.
Expect HCM to range from $12.33 to $22.17 through 2030. The $15.99 average target implies a +44% move from current prices. That is up +24% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The HCM price prediction for 2031 points to an average of $17.88 (low $13.59, high $25.21) — a potential gain of +61% on today's $11.07. Momentum favours further upside here.
In 2032, HCM is projected to trade between $13.06 and $24.91, averaging $17.39 — a potential gain of +57% from today's $11.07. That is -3% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
HUTCHMED (China) Limited's 2033 outlook centres on $18.78, within a $13.93 to $27.28 range. That is up +8% on the projected 2032 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2034, HCM could reach as high as $28.44, with a base case around $19.32 and support toward $14.18 — roughly +75% from $11.07. Buyers look set to stay in control over this stretch.
Expect HCM to range from $14.57 to $29.88 through 2035. The $20.06 average target implies a +81% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The HCM price prediction for 2040 points to an average of $27.83 (low $19.26, high $43.62) — a potential gain of +151% on today's $11.07. Buyers look set to stay in control over this stretch.
In 2050, HCM is projected to trade between $36.92 and $97.69, averaging $57.83 — a potential gain of +422% from today's $11.07. That is up +108% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HCM today (≈ 90.334237 HCM) could be worth
$5,223.64
+$4,223.64 (+422%) by 2050 · US Dollar
Based on the average projected HCM price of $57.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HCMwould be worth at today's price.
$1,000 invested in HCM on Jul 10, 2025 (≈ 62.617407 HCM) would be worth
$693.17
-$306.83 (-30.7%) today · 0.69× · US Dollar
Based on a HCM entry price of $15.97 vs. today's $11.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.44 | $967.66 | -3.2% |
| 1 month ago | $10.87 | $1,018.4 | +1.8% |
| 3 months ago | $15.24 | $726.38 | -27.4% |
| 6 months ago | $14.93 | $741.46 | -25.9% |
| 1 year ago | $15.97 | $693.17 | -30.7% |
| All time (5.0y) ago | $38.08 | $290.7 | -70.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HCM forecast.
Our base-case forecast reaches $22.00 around 2040.
Implied market cap at $22.00: $3.78B
The multi-year forecast points to meaningful upside beyond 2030. In 2030 the average price is projected at $16.67 with a max of $23.13 and an ROI of 43.1; in 2040 the average is $28.40 with a max of $44.56 and an ROI of 143.8; and in 2050 the average is $59.27 with a max of $100.27 and an ROI of 408.7. These figures imply substantial long-run upside, with bullish sentiment attributed to 2030 and beyond.
The outlook carries inherent uncertainty, and these are estimates rather than guarantees. Risk factors include market volatility and other factors not specified here.
Tap a question to reveal the answer.
2030 avg $16.67; min $12.84; max $23.13; ROI 43.1; sentiment BULLISH.
The forecast shows bullish sentiment from 2030 onward with rising averages and ROIs up to 408.7 by 2050, though near-term periods (2026–2029) show modest growth and uncertainty. These are estimates, not guarantees.
Yes, the 2050 max is $100.27, with the 2050 avg at $59.27 and a 408.7 ROI.
Current price is $11.65 and market cap is $2B.
RSI14 is 60; SMA50 is $11.78; SMA200 is $14.04; support is $9.99; resistance is $12.04; 30-day range is $10.14–$13.39.
HUTCHMED (China) Limited Community Discussion
0Share your HUTCHMED (China) Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.